MedTrace Logo

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

NCT01203618 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-11-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

Conditions

  • Resectable, Non-functioning Pituitary Adenoma

Interventions

DRUG

Farletuzumab

Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Principal Investigators

  • Bruce Wallin, MD · Morphotek

  • Nelson Oyesiku, MD, PhD, FACS · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-06-30
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203618 on ClinicalTrials.gov